The treatment of Raynaud's phenomenon.
Dowd
P M
PM
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000527:Alprostadil / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D011464:Epoprostenol / Q000627:therapeutic use; D006801:Humans; D010956:Plasmapheresis; D011928:Raynaud Disease / Q000188:drug therapy / Q000628:therapy*; D013562:Sympathectomy; D013565:Sympatholytics / Q000627:therapeutic use
D000317:Adrenergic alpha-Antagonists; D002121:Calcium Channel Blockers; D013565:Sympatholytics; D011464:Epoprostenol; D000527:Alprostadil